- Home
- LEGH vs PLRX Comparison
LEGH vs PLRX Comparison
Compare LEGH & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LEGH | PLRX |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.0M | 93.3M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LEGH | PLRX |
|---|---|---|
| Price | $19.85 | $1.22 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 11 |
| Target Price | ★ $25.00 | $3.79 |
| AVG Volume (30 Days) | 116.8K | ★ 1.9M |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.95 | N/A |
| Revenue | ★ $180,497,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.07 | N/A |
| P/E Ratio | $10.19 | ★ N/A |
| Revenue Growth | ★ 10.25 | N/A |
| 52 Week Low | $18.84 | $1.10 |
| 52 Week High | $29.45 | $14.26 |
Technical Indicators
Market Signals| Indicator | LEGH | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.49 | 36.77 |
| Support Level | $19.56 | $1.20 |
| Resistance Level | $20.94 | $1.27 |
| Average True Range (ATR) | 0.60 | 0.07 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 31.45 | 20.00 |
Price Performance
Historical ComparisonAbout LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.